A Phase II Study to Evaluate the Safety and Efficacy of KC1036 in Adolescents Aged 12 and Above With Advanced Ewing Sarcoma
Latest Information Update: 27 Aug 2024
At a glance
- Drugs KC 1036 (Primary)
- Indications Ewing's sarcoma
- Focus Adverse reactions
- Sponsors KONRUNS Pharmaceutical
Most Recent Events
- 27 Aug 2024 New trial record